-+ 0.00%
-+ 0.00%
-+ 0.00%

Advicenne H1 net sales more than double to EUR 2.7 million on French reimbursement rollout

PUBT·07/16/2026 18:11:30
Listen to the news
Advicenne H1 net sales more than double to EUR 2.7 million on French reimbursement rollout
  • Advicenne posted H1 2026 net revenue of EUR 2.7 million, up 170% from EUR 1.03 million.
  • Sibnayal direct sales rose to EUR 1.19 million from EUR 0.49 million; France Sibnayal volumes increased 41%.
  • Neurology revenue climbed to EUR 1.51 million from EUR 0.53 million, led by Likozam at EUR 1.15 million versus EUR 0.2 million.
  • Early-access rebates fell to EUR 0 from EUR 1.6 million, following French reimbursement pricing agreements for Sibnayal, Likozam.
  • Total Sibnayal end-market sales reached EUR 6.6 million, up 27% from EUR 5.2 million; related royalties expected in Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advicenne SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.